Investors

Invest in the Rocky Mountain Region

 

With over 100 new bioscience companies formed in the last 5 years out of our world class research institutions –and $716M in grant, angel and venture investments into those companies –this region knows how to grow its own successfully.   From Taligen’s investments of $69.7M and its recent acquisition by Alexion Pharmaceuticals to Globeimmune’s raise of $145M (including $40M from a 2009 partnership with Celgene –and $400M in milestone opportunities) our companies continue to lure investors and partners – and, provide exits worth noting.

 

Several of the largest Series A (Clovis Oncology $146 Million) and Series B (Taligen Therapeutics at $65 Million) investments in the nation during the past few years have been in the Rocky Mountain region.

 

 

Our bioscience companies continue to garner capital beyond the initial A & B rounds, making them some of the most successful up and coming companies in the nation:

  • Allos Therapeutics - $208M
  • Globeimmune - $145M, with $400M in milestone opportunities from Celgene
  • Array BioPharma - $120M
  • Accera - $46M
  • Inviragen - $33.8M
  • SomaLogic - $35M
  • Lanx - $25M
  • Biodesix - $18.5M
  • ARCA - $32M
  • CardioOptics - $26.5M
  • iBalance - $13M
  • miRagen - $12M
 

Successful recent exits in the Rocky Mountain region include:

  • Ventana Medical Systems, acquired by Roche for $3.4B
  • Pharmion, acquired by Celgene for $2.9B
  • Sirna, acquired by Merck for $1.1B
  • Zevex, acquired by Moog for $83.8M
  • Insmed, acquired by Merck for $130M
  • Novazyme, acquired by Genzyme for $137M
  • Taligen, acquired by Alexion Pharmaceuticals for $111M (Upfront cash payment of $111 million. Additional contingent payments earned upon reaching various clinical efficacy and product approval milestones.)

Don’t miss this chance to participate in some of the newest deals and meet those who are shaping the future landscape of the life sciences industry.